PAtients With Symptomatic Peripheral Artery Disease on Rivaroxaban-acetylsalicylic Acid Combination Therapy (PRO-PAS)
Condition(s):Peripheral Atherosclerotic DiseaseLast Updated:February 8, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Peripheral Atherosclerotic DiseaseLast Updated:February 8, 2024Recruiting
Condition(s):Atrial FibrillationLast Updated:February 8, 2024Recruiting
Condition(s):Respiratory DiseaseLast Updated:January 29, 2024Recruiting
Condition(s):Failed Back Surgery Syndrome; Limb Ischemia; Neuropathic Pain; Complex Regional Pain SyndromesLast Updated:January 29, 2024Enrolling by invitation
Condition(s):Postherpetic NeuralgiaLast Updated:January 26, 2024Enrolling by invitation
Condition(s):Deglutition Disorders; Neurological DisorderLast Updated:January 23, 2024Recruiting
Condition(s):Occupational ExposureLast Updated:January 9, 2024Recruiting
Condition(s):Renal Cell Carcinoma Metastatic; Breast Cancer; Head and Neck Cancer; Thyroid Cancer; Ovary Cancer; Lung Cancer; Stomach CancerLast Updated:March 8, 2024Completed
Condition(s):Diabetes Mellitus, Type 2; Heart Failure Preserved Ejection FractionLast Updated:September 28, 2023Recruiting
Condition(s):Breast CancerLast Updated:September 21, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.